{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:23:02Z","timestamp":1790634182205,"version":"4.1.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1097\/ftd.0000000000000004","type":"journal-article","created":{"date-parts":[[2013,12,4]],"date-time":"2013-12-04T04:41:25Z","timestamp":1386132085000},"page":"326-334","source":"Crossref","is-referenced-by-count":104,"title":["Plasma Concentrations of Tyrosine Kinase Inhibitors Imatinib, Erlotinib, and Sunitinib in Routine Clinical Outpatient Cancer Care"],"prefix":"10.1097","volume":"36","author":[{"given":"Nienke A. G.","family":"Lankheet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotte M.","family":"Knapen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan H. M.","family":"Schellens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos H.","family":"Beijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeltje","family":"Steeghs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alwin D. R.","family":"Huitema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20210129","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1056\/NEJMra044389","article-title":"Tyrosine kinases as targets for cancer therapy.","volume":"353","author":"Krause","year":"2005","journal-title":"N Engl J Med"},{"key":"R2-8-20210129","doi-asserted-by":"crossref","first-page":"5305","DOI":"10.1200\/JCO.2005.16.584","article-title":". Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.","volume":"23","author":"Burris","year":"2005","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"R3-8-20210129","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.3816\/CLC.2004.s.013","article-title":"Effect of epidermal growth factor receptor mutations on the response to epidermal growth factor receptor tyrosine kinase inhibitors: target-based populations for target-based drugs.","volume":"6","author":"Calvo","year":"2004","journal-title":"Clin Lung Cancer"},{"key":"R4-8-20210129","doi-asserted-by":"crossref","first-page":"6073","DOI":"10.1158\/1078-0432.CCR-05-2596","article-title":". Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors.","volume":"12","author":"Delbaldo","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R5-8-20210129","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1200\/JCO.2001.19.13.3267","article-title":". Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.","volume":"19","author":"Hidalgo","year":"2001","journal-title":"J Clin Oncol"},{"key":"R6-8-20210129","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00280-009-1170-y","article-title":". Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokineticpharmacodynamic meta-analysis.","volume":"66","author":"Houk","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"R7-8-20210129","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":". Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study.","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"key":"R8-8-20210129","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/sj.bjc.6604355","article-title":". Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability.","volume":"98","author":"Widmer","year":"2008","journal-title":"Br J Cancer"},{"key":"R9-8-20210129","first-page":"1011","article-title":". Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with standard of care therapeutic agents for the treatment of breast cancer.","volume":"2","author":"Abrams","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"R11-8-20210129","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.2005.02.2194","article-title":". Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.","volume":"24","author":"Faivre","year":"2006","journal-title":"J Clin Oncol"},{"key":"R12-8-20210129","first-page":"327","article-title":". In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokineticpharmacodynamic relationship.","volume":"9","author":"Mendel","year":"2003","journal-title":"Clin Cancer Res"},{"key":"R13-8-20210129","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1023\/B:CLIN.0000006873.65590.68","article-title":". SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model.","volume":"20","author":"Murray","year":"2003","journal-title":"Clin Exp Metastasis"},{"key":"R14-8-20210129","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":". Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia.","volume":"109","author":"Picard","year":"2007","journal-title":"Blood"},{"key":"R15-8-20210129","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO.2008.20.4818","article-title":". Imatinib plasma levels are correlated with clinical benefit in patients with unresectablemetastatic gastrointestinal stromal tumors.","volume":"27","author":"Demetri","year":"2009","journal-title":"J Clin Oncol"},{"key":"R16-8-20210129","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ctrv.2010.08.006","article-title":". Moving towards dose individualization of tyrosine kinase inhibitors.","volume":"37","author":"Klumpen","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"R17-8-20210129","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S1470-2045(03)01034-9","article-title":"Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy.","volume":"4","author":"Slaviero","year":"2003","journal-title":"Lancet Oncol"},{"key":"R18-8-20210129","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2165\/00003088-200544020-00002","article-title":". Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: A review.","volume":"44","author":"de Jonge","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"R21-8-20210129","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1200\/JCO.2012.43.5362","article-title":". Evidence for therapeutic drug monitoring of targeted anticancer therapies.","volume":"30","author":"Gao","year":"2012","journal-title":"J Clin Oncol"},{"key":"R22-8-20210129","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/FTD.0b013e31827efd9e","article-title":". Quantification of sunitinib and N-desethyl sunitinib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry: Validation and application in routine therapeutic drug monitoring.","volume":"35","author":"Lankheet","year":"2013","journal-title":"Ther Drug Monit"},{"key":"R23-8-20210129","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/bmc.2814","article-title":". Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry.","volume":"27","author":"Lankheet","year":"2013","journal-title":"Biomed Chromatogr"},{"key":"R24-8-20210129","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/FTD.0b013e3181b2c8cf","article-title":". A therapeutic drug monitoring algorithm for refining the imatinib trough level obtained at different sampling times.","volume":"31","author":"Wang","year":"2009","journal-title":"Ther Drug Monit"},{"key":"R25-8-20210129","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":". A method for estimating the probability of adverse drug reactions.","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmcol Ther"},{"key":"R26-8-20210129","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3324\/haematol.2011.045666","article-title":". Plasma exposure of imatinib and its correlation with clinical response in the tyrosine kinase inhibitor optimization and selectivity trial.","volume":"97","author":"Guilhot","year":"2012","journal-title":"Haematologica"},{"key":"R27-8-20210129","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1200\/JCO.2008.19.3995","article-title":". Overcoming CYP1A11A2 mediated induction of metabolism by escalating erlotinib dose in current smokers.","volume":"27","author":"Hughes","year":"2009","journal-title":"J Clin Oncol"},{"key":"R28-8-20210129","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1158\/0008-5472.CAN-04-2416","article-title":". The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients.","volume":"65","author":"Breedveld","year":"2005","journal-title":"Cancer Res"},{"key":"R29-8-20210129","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1177\/1078155210381794","article-title":"Should the concomitant use of erlotinib and acid-reducing agents be avoided The drug interaction between erlotinib and acid-reducing agents.","volume":"17","author":"Duong","year":"2011","journal-title":"J Oncol Pharm Pract"},{"key":"R30-8-20210129","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1182\/blood-2010-07-294330","article-title":". Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib.","volume":"117","author":"Haouala","year":"2011","journal-title":"Blood"},{"key":"R31-8-20210129","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00210-001-0489-7","article-title":". Interaction of omeprazole, l ansoprazole and pantoprazole with P-glycoprotein.","volume":"364","author":"Pauli-Magnus","year":"2001","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"R33-8-20210129","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s12185-009-0315-4","article-title":". Relationship between an effective dose of imatinib, body surface area, and trough drug levels in patients with chronic myeloid leukemia.","volume":"89","author":"Kawaguchi","year":"2009","journal-title":"Int J Hematol"},{"key":"R34-8-20210129","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.3109\/10428194.2011.563885","article-title":". Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia.","volume":"52","author":"Sohn","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"R35-8-20210129","doi-asserted-by":"crossref","first-page":"470","DOI":"10.2174\/138920009788897975","article-title":". Tyrosine kinase inhibitorsa review on pharmacology, metabolism and side effects.","volume":"10","author":"Hartmann","year":"2009","journal-title":"Curr Drug Metab"},{"key":"R36-8-20210129","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/j.ejca.2009.02.011","article-title":". Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.","volume":"45","author":"George","year":"2009","journal-title":"Eur J Cancer"},{"key":"R37-8-20210129","doi-asserted-by":"crossref","first-page":"5780","DOI":"10.1158\/1078-0432.CCR-12-0490","article-title":". A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients.","volume":"18","author":"Eechoute","year":"2012","journal-title":"Clin Cancer Res"},{"key":"R38-8-20210129","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-2125.2006.02719.x","article-title":". Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein.","volume":"62","author":"Widmer","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"R39-8-20210129","doi-asserted-by":"crossref","first-page":"198","DOI":"10.2174\/157488408785747656","article-title":"Schleyer E, von BM, et al.. Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients.","volume":"3","author":"Pursche","year":"2008","journal-title":"Curr Clin Pharmacol"},{"key":"R40-8-20210129","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2165\/11593320-000000000-00000","article-title":". Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.","volume":"50","author":"Di Gion","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"R41-8-20210129","doi-asserted-by":"crossref","first-page":"6062","DOI":"10.1158\/1078-0432.CCR-09-0048","article-title":". Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters.","volume":"15","author":"Hu","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R42-8-20210129","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/ijc.26000","article-title":". Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.","volume":"130","author":"Tang","year":"2012","journal-title":"Int J Cancer"},{"key":"R43-8-20210129","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1016\/j.ejca.2009.05.007","article-title":". Population pharmacokinetics of erlotinib and its pharmacokineticpharmacodynamic relationships in head and neck squamous cell carcinoma.","volume":"45","author":"Thomas","year":"2009","journal-title":"Eur J Cancer"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T20:27:54Z","timestamp":1620937674000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201406000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000004","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]}}}